Title:

Farnesol attenuates oxidative stress and liver injury and modulates fatty acid synthase and acetyl-CoA carboxylase in high cholesterol-fed rats

Authors and affiliations:

Mohammad H. Abukhalil1,2#, Omnia E. Hussein3#, May Bin-Jumah4, Sultan A. M. Saghir1, Mousa O. Germoush5, Hassan A. Elgebaly5, Nermeen M. Mosa5, Ismail Hamad6,7, Moath M. Qarmush8, Emad M. Hassanein9, Emadeldin M. Kamel10, Rene Hernandez-Bautista11, Ayman M. Mahmoud3\*

1 Department of Medical Analysis, Princess Aisha Bint Al-Hussein Faculty of Nursing and Health Sciences, Al-Hussein Bin Talal University, Jordan.

2 Department of Biology, Faculty of Science, Al-Hussein Bin Talal University, Jordan.

3 Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef University, Egypt.

4 Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Saudi Arabia.

5 Department of Biology, College of Science, Jouf University, Saudi Arabia.

6 College of Applied Medical Sciences, Jouf University, Saudi Arabia.

7 Biochemistry Department, Bahri University, Sudan

8 College of Medicine, Jouf University, Saudi Arabia.

9 Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University-Assiut Branch, Egypt.

10 Chemistry Department, Faculty of Science, Beni-Suef University, Egypt.

11 Institute for Diabetes and Obesity, Helmholtz Center Munich, Neuherberg, Germany.

# contributed as first author.

Corresponding author:

Ayman M. Mahmoud, PhD

Physiology Division

Department of Zoology

Faculty of Science

Beni-Suef University, Beni-Suef, Egypt.

E-mail: [ayman.mahmoud@science.bsu.edu.eg](mailto:ayman.mahmoud@science.bsu.edu.eg)

**Abstract:**

Dyslipidemia is a risk factor for cardiovascular disease, steatohepatitis and progression of liver disorders. This study investigated the protective effect of farnesol (FAR), a sesquiterpene alcohol, against liver injury in high cholesterol diet (HCD)-fed rats, and its modulatory effect on fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). HCD was supplemented for ten weeks and the rats were concurrently treated with FAR. Rats received HCD exhibited significant elevation of serum cholesterol, triacylglycerols, LDL- and vLDL-cholesterol, CRP and pro-inflammatory cytokines and increased values of the cardiovascular risk indices. Serum transaminases, ALP, LDH and CK-MB, and hepatic lipid peroxidation (LPO), cholesterol and triacylglycerols were increased in HCD-fed rats. Treatment with FAR greatly ameliorated dyslipidemia and liver function, reduced inflammatory mediators, LPO, and hepatic lipid infiltration, and enhanced antioxidant defenses. FAR suppressed hepatic FAS, ACC and SREPB-1c mRNA abundance and FAS activity in HDC-fed rats. In addition, molecular docking simulations pinpointed the binding modes of FAR to the active pocket residues of FAS and ACC. In conclusion, FAR possesses a strong anti-hyperlipidemic/anti-hypercholesterolemic activity mediated through its ability to modulate hepatic FAS, ACC and SREPB-1c. FAR prevented oxidative stress, inflammation and liver injury induced by HCD. Thus, FAR may represent a promising lipid-lowering agent that can protect against dyslipidemia and its linked metabolic deregulations.

**Keywords:** Sesquiterpenes; Hypercholesterolemia; Farnesol; Molecular docking; Oxidative stress; Steatosis

**Introduction**

Dyslipidemia is an abnormal lipid metabolism representing the primary risk factor in the development of cardiovascular and hepatic diseases (Sozen &Ozer 2017). Lipid metabolism imbalance may result from the interaction between genetics and environmental factors, such as eating habits, especially the excessive consumption of foods rich in cholesterol and saturated fats (Bin-Jumah 2018, Ordovas 2009). Extensive evidence has demonstrated the key role of hyperlipidemia, particularly hypercholesterolemia, in the initiation of cardiovascular events in patients with cardiovascular disease (CVD) (Cífková &Krajčoviechová 2015, Han et al. 2018). In addition, it has been reported that excess accumulation of cholesterol in liver may lead to hepatotoxicity characterized by increased inflammatory cells infiltration, hepatocyte degenerative changes and fibrosis (AlSharari et al. 2016, Farrell &Larter 2006, Muniz et al. 2019, Sozen &Ozer 2017). Furthermore, increased lipid levels in endothelial cells, hepatocytes, cardiomyocytes, leukocytes and erythrocytes may increase reactive oxygen species (ROS) production, oxidative degradation of lipids and membrane destabilization that eventually lead to cellular dysfunction and death (Förstermann 2008, Küçükgergin et al. 2010, Sozen &Ozer 2017). A recent study has reported that feeding a high cholesterol diet (HCD) increased serum transaminases, and pro-inflammatory mediators and caused hepatic and cardiac oxidative damage in rats (Bin-Jumah 2018). Therefore, the prevention of lipid imbalance is important to prevent and treat various vascular and hepatic diseases.

Lipid accumulation in liver can occur as a result of increased synthesis and uptake of fatty acids (FAs) and/or reduced FA oxidation (Orellana-Gavalda et al. 2011, van Herpen &Schrauwen-Hinderling 2008). Recently, fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) have become interesting targets to assist in finding therapeutics for the treatment of obesity and hypercholesterolemia (Lu &Archer 2005). FAS, a key enzyme in the biosynthesis of FAs, catalyzes the synthesis of palmitate from acetyl-CoA, malonyl-CoA and NADPH (Smith et al. 2003). FAS comprises seven catalytic domains (ketoacyl ACP synthase (KS), hydroxyacyl ACP dehydratase (HD), ketoacyl ACP reductase (KR), acyl transferase (AT), enoyl ACP reductase (ER), malonyl CoA-ACP transferase (MT), and thioesterase (TE)) distributed around a central acyl carrier protein (ACP) (Chirala &Wakil 2004). Each subunit is responsible for a certain function in the synthesis of palmitate. The TE domain was identified as the main factor controlling the last step of FAs synthesis, particularly the release of palmitate by the hydrolysis of thioester linkage in palmitoyl-S-ACP (Chirala &Wakil 2004). The KS domain is responsible for the production of various lengths FAs (Witkowski et al. 2002). ACC is a biotin-dependent enzyme catalyzing the production of malonyl-CoA from acetyl-CoA. This ACC-catalyzed reaction is an important step in modulating both the biosynthesis and oxidation of FAs (Xiang et al. 2009). ACC consists of biotin carboxylase (BC), biotin carboxy carrier protein (BCCP), and carboxy transferase (CT) domains (Corbett et al. 2010). The binding modes of the active inhibitors with FAS and ACC are still a matter of debate. The lack of this knowledge has increased the curiosity toward better understanding of the interactions of these enzymes with reactive drugs.

The use of plants and their products in the treatment of hyperlipidemia is an ongoing approach worldwide. Indeed, natural compounds with antioxidant and lipid-lowering actions may confer beneficial effects against the serious pathological consequences of cholesterol accumulation in certain tissues, such as liver and heart. Farnesol (FAR; 3,7,11-trimethyldodeca-2,6,10-trien-1-ol) is a sesquiterpene alcohol widely distributed in fruits, vegetables, essential oils and herbs. Peaches, tomatoes, corn, chamomile, lemon grass, and citronella and ambrette seeds oils are among the sources of FAR (Goto et al. 2011, Jung et al. 2018, Tatman &Mo 2002). Numerous biological activities of FAR, including antioxidant, anti-inflammatory, anti-obesity, hepatoprotective and cardioprotective effects have been documented (Jung et al. 2018, Kim et al. 2017, Lateef et al. 2013). FAR protected the lungs against cigarette smoke-induced injury by mitigating inflammation and oxidative stress in rats (Santhanasabapathy et al. 2015). Besides, FAR was shown to ameliorate acrylamide-induced inflammation and neurotoxicity in mice by suppressing inflammatory mediators (Qamar &Sultana 2008). FAR has also prevented ischemia/reperfusion (I/R) injury by increasing protein geranylgeranylation and enhancing antioxidant activity in cardiomyocytes (Szűcs et al. 2013), and protected against calcium overload-induced arrhythmia through decreasing ROS generation in rats (de Souza et al. 2019). Moreover, FAR has been shown to modulate lipid profile by reversing the aberrated low-density lipoprotein (LDL)-cholesterol/high-density lipoprotein (HDL)-cholesterol and HDL cholesterol/total cholesterol ratios in asthmatic mice (Ku &Lin 2015). Another study showed that FAR reduced serum triglyceride (TG) and enhanced metabolic abnormalities by regulating PPARα in hepatocytes (Goto et al. 2011). FAR has also been shown to suppress 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a key enzyme in cholesterol synthesis (Meigs et al. 1996), and inhibit phosphatidylcholine synthesis human leukemic CEM-C1 cell line (Voziyan et al. 1993) and *de novo* synthesis of TG in hepatocytes (Hiyoshi et al. 2003). However, the exact anti-hypercholesterolemic mechanism of FAR remains to be further elucidated. Therefore, this study was conducted to explore the mechanism by which FAR may exert beneficial effects on lipid metabolism through studying its effect on hepatic LDL receptor (LDLR), FAS, ACC and sterol regulatory element-binding protein-1c (SREPB-1c) in HCD-fed rats. We have also investigated the binding interactions between FAR and ACC and FAS by molecular docking simulations. Furthermore, the protective effect of FAR against hypercholesterolemia-induced oxidative stress and inflammation in the liver of rats was assessed.

**Materials and Methods**

**Experimental animals and treatments**

7-week-old male albino Wistar rats of 140-160 g body weight obtained from VACSERA (Giza, Egypt) were included in this study. The animals were housed under standard conditions (temperature: 23±2°C) and a 12 h light/dark cycle) and acclimatized for one week before starting the experiment with free access to food and water.

Thirty rats were randomly allocated into five groups (*n* = 6) as follows:

Group I (Control): received normal diet for 10 weeks.

Groups II (HCD): received HCD (normal diet supplemented with 2% cholesterol) for 10 weeks (Bin-Jumah 2018).

Group III (HCD + 5 mg/kg FAR): received HCD and 5 mg/kg/day FAR (Sigma, USA) for 10 weeks.

Group IV (HCD + 10 mg/kg FAR): received HCD and 10 mg/kg/day FAR for 10 weeks.

Group V (HCD + SIM): received HCD and 10 mg/kg/day simvastatin (SIM) (Al-Rasheed et al. 2015) for 10 weeks.

FAR was dissolved in corn oil and the doses were selected according to previous studies showing its antioxidant and anti-inflammatory activities in different experimental models (Kim et al. 2017, Lateef et al. 2013, Ong et al. 2006). FAR has been supplemented at doses range from 5 to 250 mg/kg body weight. The 5 mg/kg dose exerted an anti-obesity effect in high fat diet (HFD)-fed mice (Kim et al. 2017) and hence selected along with a higher dose in this study. FAR and SIM were supplemented orally and groups I and II received the vehicle for 10 weeks.

**Collection and preparation of samples**

Twenty-four h after the last treatment, overnight fasted rats were sacrificed under thiopental (Eipico, Egypt) anesthesia, and blood was collected via cardiac puncture. Serum was prepared and used for the analysis of cholesterol, TG, HDL-cholesterol, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase-MB (CK-MB), C-reactive protein (CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β. The rats were sacrificed, dissected and liver was excised. Small pieces from the liver were fixed in 10% neutral buffered formalin for histological investigation and other pieces were frozen at −80°C. Other samples were homogenized (10% w/v) in cold PBS, centrifuged and the clear homogenate was used for the assessment of different biochemical parameters.

**Biochemical assays**

*Determination of lipids and cardiovascular risk indices*

Total cholesterol, TG and HDL-cholesterol in serum were determined using colorimetric assay kits (Spinreact, Spain) following the provided instructions. LDL- and vLDL-cholesterol, cardiovascular risk indices (Ross 1992) and antiatherogenic index (AAI) (Guido &Joseph 1992) were calculated using the formulas:

vLDL-cholesterol = Triglycerides/5

LDL-cholesterol = Total cholesterol – (HDL-cholesterol + vLDL-cholesterol)

Cardiovascular risk index 1 = Total-cholesterol/HDL-cholesterol

Cardiovascular risk index 2 = LDL-cholesterol/HDL-cholesterol

AAI = HDL-cholesterol x 100/Total cholesterol - HDL-cholesterol.

To determine hepatic cholesterol and TG levels, total lipids were extracted according to Folch et al (1957). Cholesterol and TG were measured using Spinreact (Spain) kits.

*Determination of liver and heart function markers, CRP and pro-inflammatory cytokines*

Serum ALT, AST, ALP, LDH and CK-MB were estimated using kits supplied by Spinreact (Spain). Serum levels of CRP, TNF-α, IL-1β and IL-6 were measured employing ELISA kits (R&D Systems, USA). All measurements were conducted following the manufactures' guidelines.

*Assay of lipid peroxidation (LPO), antioxidant defenses and FAS activity*

Malondialdehyde (MDA), a marker of LPO (Ohkawa et al. 1979), reduced glutathione (GSH) (Beutler et al. 1963), SOD (Marklund &Marklund 1974), and CAT (Cohen et al. 1970) were assayed in the supernatant of homogenized liver samples. FAS activity was assayed following the method described by Goodridge (Goodridge 1972). The assay depends on following the decrease in absorbance resulting from NADPH oxidation at 340 nm following the addition of malonyl-CoA. FAS activity was expressed as nmol reduced NADPH/min/mg protein. Total protein content was determined using Bradford reagent (Bradford 1976).

**Histological examination of liver sections**

Liver specimens were obtained and washed in ice-cold PBS and immediately fixed in 10% formalin for 24 h at 4°C. After fixation, the specimens were dehydrated and processed for embedding in paraffin wax. Five-μm sections were obtained using microtomy and then stained with hematoxylin and eosin (H&E) for microscopic examination.

**Gene expression analysis**

The mRNA expression levels of LDLR, FAS, ACC and SREPB-1c were quantified using qRT-PCR. Briefly, total RNA was extracted from frozen tissue samples using TRIzol (Invitrogen, USA). RNA samples were treated with RNase-free DNase and quantiﬁed at 260 nm. The quality of the RNA samples was examined using formaldehyde-agarose electrophoresis and the purity was determined using OD260/OD280 nm absorption ratio ≥ 1.8. Next, 2µg RNA was reverse transcribed and the obtained cDNA was amplified using QuantiFast SYBR Green RT-PCR kit (Qiagen, Germany) and primers in Table 1. The obtained data were analyzed using the 2ΔΔCt method (Livak &Schmittgen 2001) and normalized to β-actin.

**Molecular docking**

The initial 3D structure of FAR was constructed using gaussview 6. The geometry of FAR was optimized at the B3LYP level of theory with the 6-311G (d, p) basis set (Becke 1993). The output was converted to .pdb 3D structures using UCSF Chimera (Pettersen et al. 2004). Autodock Tools (ADT) v1.5.6 and AutoDock Vina software packages were employed for molecular docking simulations (Trott &Olson 2010). FAR was optimized for docking by using ADT. To visualize the binding mode FAR-protein complexes, the PyMOL v2.3.2 program was employed. X-ray crystal structure of the ACC used for docking was obtained from the protein data bank (PDB ID: 3TV5). Human FAS domains were utilized for docking, namely KS (PDB ID:3HHD) and TE (PDB ID: 1XKT). Macromolecules were viewed and isolated from ligands, solvent and nonstandard residues by using UCSF Chimera. Separated proteins were set for docking by optimization using ADT. The optimization includes addition of polar hydrogens and adjusting the grid box according to the suitable configuration of the active site residues (Cheng et al. 2008). The size of grid box for ACC was set at 60 x 60 x 75 (x,y,z). The KS and TE the grid boxes were placed at 60 x 60 x 60 (x,y,z) and 50 x 50 x 50 (x,y,z), respectively.

**Statistical analysis**

The obtained results were represented as mean ± standard error of the mean (SEM). All statistical comparisons were determined by one-way ANOVA and Tukey's test using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). Data of the body weight changes were analyzed by two-way ANOVA and Tukey's test. A P value <0.05 was considered significant.

**Results**

**Effect of FAR on body weight of HCD-fed rats**

Body weight was steadily increased in all groups as represented in Figure 1A. At weeks 8-10, HCD-fed rats exhibited a significant increase in body weight (P<0.001) when compared with the control rats (Fig. 1B). Treatment with FAR and SIM prevented the HCD-induced significant increase in body weight (P<0.001).

**FAR attenuates dyslipidemia in HCD-fed rats**

To assess the anti-dyslipidemia effect of FAR, serum lipids were measured. HCD supplementation caused a significant increase in serum TG (Fig. 2A), total cholesterol (Fig. 2B), LDL-cholesterol (Fig. 2C), and vLDL-cholesterol (Fig. 2D), while it did not significantly alter serum HDL-cholesterol levels (Fig. 2E). Treatment with FAR (5 and 10 mg/kg) or SIM significantly reinstated HCD-induced increased serum lipids near to the normal levels. HCD-fed rats received FAR or SIM showed non-significant changes in serum HDL-cholesterol.

HCD-supplemented rats exhibited a significant elevation in the values of total cholesterol/HDL-cholesterol (Fig. 3A), and LDL-cholesterol/HDL-cholesterol ratios (Fig. 3B). On the other hand, there was a significant reduction in AAI in HCD-fed rats (Fig. 3C). Remarkably, treatment with FAR or SIM alleviated these cardiovascular risk indices.

**FAR prevents hepatic lipid accumulation and tissue injury in HCD-fed rats**

Liver cholesterol and TG content, and serum transaminases, ALP and LDH were determined and a histological investigation was carried out to investigate the ameliorative effect of FAR on HCD-induced liver injury. HCD feeding for 10 weeks resulted in increased hepatic cholesterol (Fig. 4A) and TG (Fig. 4B) significantly (P<0.001) when compared with the control rats. Treatment with FAR (5 and 10 mg/kg) and SIM decreased liver cholesterol and TG levels in HCD-fed rats. In addition, histological examination revealed fatty infiltrations and hepatic vacuolations in the liver of HCD-fed rats (Fig. 5B) when compared with the control rats which showed normal structure of the hepatic lobules, hepatocytes and sinusoids (Fig. 5A). Rats received 5 and 10 mg/kg FAR (Fig. 5C and 5D, respectively) and SIM (Fig. 5E) showed remarkable reduction in the infiltration of fats with only mild vacuolations were observed. Furthermore, there was a significant (P<0.001) increase in serum ALT, AST, ALP, and LDH in HCD-fed rats (Fig. 6A-D), indicating hepatic injury. All these changes were significantly ameliorated in HCD-fed rats treated with FAR or SIM. Serum CK-MB was determined to evaluate the cardioprotective efficacy of FAR. While the HCD-fed rats exhibited a significant elevation in serum CK-MB, FAR-treated groups showed a significant reduction (Fig. 6E).

**FAR diminishes hepatic LPO and enhances antioxidants in HCD-fed rats**

Since hypercholesterolemia may induce oxidative stress, this study also evaluated the effect of FAR on LPO and antioxidant defenses in the liver of HCD-fed rats. There was a significant increase in hepatic MDA (Fig. 7A; P<0.001) and decreased GSH (Fig. 7B; P<0.001), SOD (Fig. 7C; P<0.001) and CAT (Fig. 7D; P<0.01) in rats supplemented a HCD for 10 weeks. Remarkably, treatment with FAR (5 and 10 mg/kg) or SIM attenuated oxidative stress in the liver as evidenced by decreased LPO and increased GSH and antioxidant enzymes.

**FAR suppresses inflammation in HCD-fed rats**

To evaluate the possible role of inflammation in HCD-induced liver injury and the protective effects of FAR, serum CRP and pro-inflammatory cytokines were assayed. There was a significant (P<0.001) increase in CRP (Fig. 8A), TNF-α (Fig. 8B), IL-6 (Fig. 8C), and IL-1β (Fig. 8D) levels in rats received HCD for 10 weeks when compared with the control group. Nevertheless, treatment with FAR or SIM significantly (P<0.001) ameliorated serum levels of CRP and cytokines.

**FAR modulates hepatic LDLR, SREBP-1c, FAS and ACC in HCD-fed rats**

To understand the anti-dyslipidemia activity of FAR in HCD-fed rats, we evaluated its effect on key factors involved in *de novo* lipogenesis, namely SREBP-1c, FAS and ACC as well as LDLR. While LDLR (Fig. 9A) showed non-significant changes upon HCD feeding, SREBP-1c (Fig. 9B) FAC (Fig. 9C) and ACC (Fig. 9E) mRNA abundance were significantly (P<0.001) increased in the liver of HCD-fed rats. Moreover, hepatic FAS activity was significantly increased in HCD-fed rats (Fig. 9D) as compared to the control rats. Interestingly, FAR and SIM significantly restored hepatic mRNA levels of LDLR, SREBP-1c, FAS and ACC as well as FAS activity.

To further explore the modulatory effect of FAR on FAS and ACC, we performed molecular docking analysis to figure out their binding modes. FAR was shown to dock into the determined active site of TE domain of FAS, as represented in Figure 10A,B. A detailed investigation of the binding site indicated that FAR forms four hydrogen bonds with the residues Ser2308, Asp2338, His2481 and Arg2482 in FAS. In addition, FAR was placed in the binding cavity encased by the hydrophobic residues Leu2222, Ile2250, Glu2251, Phe2370, Phe2371 Gln2374, Phe2423. The binding affinity was −5.2 kcal/mol, indicating the formation of a stable FAR-FAS/TE domain complex. These polar and hydrophobic interactions reflect the stability of FAR binding pattern with TE. Three phenylalanine residues (Phe2370, Phe2371 and Phe2432) were closely detected in the binding site of FAR-FAS/TE domain complex. This information is of particular interest, since it shed the light on the probability for these residues to exhibit a thermodynamically favorable π-π interactions. These interactions are likely to contribute in the binding mechanism of FAR with FAS.

The *in-silico* model for the interaction of KS domain of FAS with FAR was developed by our molecular docking studies. FAR was located in the binding site surrounded by residues Cys161, Met205, Tyr222, Pro264, His293, Thr295, Thr297, Gln303, His331, Phe393, Gly394 and Phe395. Also, FAR formed two hydrogen bonds with residues Gln269 and Gly300, as shown in Figure 10C,D. A lower binding energy was obtained for this complex than its TE domain counterpart (-6.7 kcal/mol). Two phenylalanine residues in the hydrophobic pocket make this interaction more susceptible to stabilization by π-π interaction effects.

The binding interaction between FAR and human ACC was represented in Figure 10E,F. Three polar bonds were detected in the FAR-ACC complex with residues Ser1808 and Arg1883, and occupied hydrophobic pocket comprises the residues Gln1522, Asn1525, Phe1526, Pro1574, Glu1575, Glu1805, Tyr 1809, Leu1821, Lys1863 and Gly1864. The complex formed is stable and the lowest binding energy was −5.5 kcal/mol. The estimated binding pocked in this complex showed one phenylalanine and one tyrosine residues, namely Phe1526 and Tyr1809. These residues are capable of making π-π interactions that could potentially show thermodynamically favorable interactions with the pi bonds of the inhibitor. Figure 8E shows the structure of the potential depth in the binding cavity of FAR-ACC binding pocket. This figure implies that FAR is located mainly inside the binding pocket of ACC.

**Discussion**

Hypercholesterolemia is a well-acknowledged causative risk factor for the development of CVD and liver injury (Sozen &Ozer 2017). Thus, hypocholesterolemic strategies could be effective in preventing metabolic disorders associated with dyslipidemia. Herein, we investigated the potential of FAR to prevent liver injury in HCD-fed rats, pointing to its ability to suppress oxidative stress, inflammation and lipogenic factors. Our results showed that FAR effectively attenuated dyslipidemia, oxidative stress and liver injury, and modulated SREBP-1c, FAS and ACC.

HCD feeding has been reported to establish an experimental model mimicking hypercholesterolemia pathophysiology in human (Shi et al. 2019). Consistent with several previous studies (AlSharari et al. 2016, Bin-Jumah 2018, Shi et al. 2019), HCD caused dyslipidemia manifested by increased serum cholesterol, TG, and LDL and vLDL. Hypercholesterolemia can lead to hepatic lipid accumulation resulting in chronic inflammation, degenerative changes, hepatotoxicity, fibrosis and liver failure (AlSharari et al. 2016, Farrell &Larter 2006, Muniz et al. 2019, Sozen &Ozer 2017). Accordingly, cholesterol and TG were increased in the liver of HCD-fed rats and histological examination revealed massive lipid infiltration. Increased accumulation of lipids in the liver can impact its ability to metabolize lipids, resulting in dyslipidemia (Arvind et al. 2000). HCD-induced liver injury has been further confirmed by elevated serum transaminases, ALP and LDH. These enzymes are the most frequently used indicators for the assessment of liver injury and are considered valuable markers of degenerative and necrotic changes in hepatocytes (McGill 2016). Here, treatment with FAR and SIM reduced serum lipids and hepatic cholesterol and TG contents in HCD-fed rats. In addition, the histopathological findings revealed a remarkable reduction in hepatic lipid infiltration following treatment with FAR or SIM. FAR has also reduced serum ALT, AST, ALP and LDH in HCD-fed rats, demonstrating a potent hepatoprotective activity. In this context, FAR showed a protective effect against cyclophosphamide (CP) hepatotoxicity in mice (Araghi et al. 2018). Treatment with FAR reduced serum ALT and AST and preserved the normal architectural integrity of liver in CP-intoxicated mice (Araghi et al. 2018). Hypercholesterolemia may also impact the myocardium resulting in contractile dysfunction, I/R injury, and diminished stress adaptation (Csonka et al. 2016, Huang et al. 2004, Osipov et al. 2009). Therefore, lipid-lowering strategies might help counteracting the negative impact of hypercholesterolemia on the heart. The present study demonstrated that HCD-fed rats showed significantly elevated cardiovascular risk indices and reduced AAI, coupled with increased serum levels of CK-MB, a key biomarker of heart function, which were remarkably attenuated by FAR treatment. Thus, these findings indicate that the antihyperlipidemic effect of FAR mediated its cardioprotective action.

Given that cholesterol-enriched diet was reported to induce oxidative stress in various tissues (Abbas &Sakr 2013, Bin-Jumah 2018, Kocsis et al. 2009), we assumed that the antioxidant activity of FAR plays a role in its hepatoprotective efficacy. Hypercholesterolemia has been implicated in oxidative modification of LDL, protein glycation and glucose autooxidation (Singh et al. 2017, Yang et al. 2008). Besides, high cholesterol levels can lead to increased cholesterol pool, which results in changes in cell membrane physical properties, facilitating the leakage of ROS from the mitochondrial electron system or the activation of NADPH oxidase and xanthine oxidase, eventually culminating in LPO and protein oxidation (Singh et al. 2017, Varga et al. 2013). Here, HCD-fed rats showed an increase in MDA coupled with decreased GSH and activity of the antioxidant enzymes. LPO alters fluidity and permeability of cell membranes and inactivate membrane-bound receptors and enzymes, leading to destruction of the membrane (Singh et al. 2017, Smathers et al. 2011). Moreover, increased ROS production can promote oxidation of the antioxidant enzymes and therefore abolish the cellular antioxidant capacity (Smathers et al. 2011). Therefore, attenuation of hypercholesterolemia-induced oxidative stress could represent an effective strategy to prevent or treat metabolic abnormalities in hyperlipidemic subjects. In the present study, FAR diminished LPO and boosted GSH and antioxidant enzymes in the liver of HCD-fed rats. Consistently, FAR prevented CP-induced oxidative damage in mice liver (Araghi et al. 2018) and protected against cigarette smoke-induced oxidative stress in rats prostate (Lateef et al. 2013) through inhibition of LPO and maintaining antioxidants defenses. FAR also showed a protective effect against cadmium-induced renal oxidative and genotoxic damages through inhibition of xanthine oxidase and LPO in mice (Jahangir et al. 2005). Thus, FAR can protect against HCD-induced liver injury by suppressing oxidative stress and restoring antioxidant defenses.

In addition to oxidative stress, HCD-fed rats showed elevated serum CRP and pro-inflammatory cytokines. Indeed, hypercholesterolemia-induced sustained ROS production can elicit stress signaling and pro-inflammatory pathways, particularly, NF-κB signaling which is a redox-sensitive factor controlling the transcriptional regulation of IL-1β, IL-6 and TNF-α. Here, serum levels of IL-1β, IL-6 and TNF-α were elevated in HCD-fed rats. In addition, oxidized LDL promotes the expression of cytokines and chemokines; thereby, magnify the inflammatory response, leading to macrophage activation and more ROS generation (Lara-Guzmán et al. 2018). Within a hypercholesterolemic environment, various pathological conditions, including nonalcoholic fatty liver disease (NAFLD) and atherosclerosis can be exacerbated in the presence of systemic inflammation (Kim et al. 2014). FAR mitigated the circulating levels of pro-inflammatory mediators, demonstrating an anti-inflammatory effect. In the same context, FAR suppressed inflammation in cigarette smoke-induced lung injury- (Qamar &Sultana 2008) and acrylamide-induced neurotoxicity (Santhanasabapathy et al. 2015) in rodents.

The hepatoprotective activity of FAR could be directly connected to its anti-hypercholesterolemia efficacy. The present study explored the possible involvement of SREPB-1c, FAS and ACC in the anti-hypercholesterolemic activity of FAR. Consistent with several previous studies (Bin-Jumah 2018, Lee et al. 2017, Ren et al. 2018), dyslipidemic rats showed a significant increase in hepatic mRNA of SREPB-1c, FAS and ACC. SREPB-1c is a transcription factor that regulates the expression of genes for both cholesterol and FA synthesis, including ACC and FAS, and affects the lipid accumulation induced by HFD (Horton et al. 2002). ACC and FAS have been targeted as potential intervention points for the treatment of metabolic diseases such as hyperlipidemia (Ren et al. 2018). In the present study, treatment of HCD-fed rats with FAR significantly decreased mRNA expression of liver FAS, ACC and SREPB-1c as well as FAS activity which can explain the observed lipid-lowering action of FAR. The suppressive effect of FAR on FAS and ACC was further investigated using molecular docking simulations. The binding affinity, hydrogen bonds and hydrophobic interactions of FAR with ACC and FAS catalytic subunits (TE and KS) were predicted by molecular docking analysis. FAR showed both polar and hydrophobic interactions with ACC and the FAS subunits TE and KS. The TE domain is known to catalyze the liberation of the final product (palmitate) from FAS by the hydrolysis of the thioester bond in palmitoyl-S-ACP. Within the seven domains of FAS, KS is known to act as an important regulator of the produced fatty acid chain length (Cheng et al. 2008, Chirala &Wakil 2004, Witkowski et al. 2002). Polar and hydrophobic interactions play a crucial role in stabilizing geometrical structures of biological macromolecules as DNA, lipids and proteins. Particularly, hydrogen bonding is considered to be the main factor responsible for the binding of ligands into the active sites of proteins. Consequently, they contribute to the affinity, molecular recognition and orientation of the drug (Kubinyi 2001). The binding affinity is positively influenced by hydrophobic interactions between the lipophilic surfaces of a drug and hydrophobic zones of its binding cavity, and the total share of polar interactions to these affinities is mainly depends on desolvation energy and recently formed hydrogen bonding (Kubinyi 2001). Therefore, a perfect geometrical coincidence of a drug with the binding site is essential for a favorable protein-ligand interaction. As well, optimized geometry ligands, formation of neutral and/or charged polar bonds and hydrophobic interactions are factors affecting the thermodynamic balance and energies of interactions (Kubinyi 2001). The agreement between docking results and the molecular and biochemical assays suggests that the affinity between FAS and ACC enzymes and FAR would provide the inhibitor with a preferable potential to exert ani-hyperlipidemia activity.

Besides the modulation of FAS and ACC, other effects of FAR contribute to its anti-dyslipidemia activity. HCD has been acknowledged to stimulate HMG-CoA reductase activation and increase its mRNA and protein expression, resulting in elevated serum LDL and hepatic cholesterol accumulation (Min et al. 2012, Shi et al. 2019). FAR has been reported to suppress and accelerate the degradation of HMG-CoA reductase (Meigs et al. 1996), thereby decreasing cholesterol synthesis. In a rat model of hepatocarcinogenesis, FAR reduced plasma cholesterol and hepatic HMG-CoA reductase mRNA (Ong et al. 2006). Recently, Pant et al demonstrated that FAR stimulated PPARα-mediated induction of FAs oxidation and suppressed TG accumulation in hepatic steatosis (Pant et al. 2019). In HFD-fed obese KK-Ay mice, FAR ameliorated the metabolic abnormalities via PPARα both dependent and independent pathways and suppressed SREBP-1c gene expression (Goto et al. 2011). Additionally, our results showed that FAR significantly increased the expression of LDLR which plays a crucial role in cholesterol homeostasis. LDL-cholesterol uptake mediated by LDLR is an effective way of reducing circulating cholesterol (Zelcer et al. 2009), and recent studies have demonstrated elevated serum and hepatic cholesterol levels in LDLr−/− mice fed a HFD (Emini Veseli et al. 2017, Sun et al. 2017). Increased phosphorylation of AMP-activated protein kinase (AMPK) is another mechanism that might be involved in the anti-hypercholesterolemic effect of FAR. AMPK plays a central role in FAs metabolism where its activation suppresses FAS and ACC and stimulates FAs β-oxidation by reducing malonyl-CoA levels (Kahn et al. 2005). The lack of data showing the effect of FAR on AMPK phosphorylation is a limitation of this study. However, FAR inhibited white adipogenesis and promoted the development of beige adipocytes in 3T3-L1 cells and human adipose tissue-derived mesenchymal stem cells, respectively, through AMPK activation (Kim et al. 2017).

**Conclusions**

FAR attenuated hypercholesterolemia and reduced hepatic lipid accumulation and injury in HCD-fed rats. FAR reduced serum and hepatic lipids, increased LDL-cholesterol clearance, attenuated oxidative stress and inflammation. The lipid-lowering efficacy of FAR was associated with up-regulation of LDLR and down-regulation of SREPB-1c, FAS and ACC. In addition, the results showed a good correlation between the *in silico* determined binding affinity of FAR with FAS and ACC and the *in vivo* findings. Therefore, FAR is an effective cholesterol-lowering agent that can attenuate liver injury and the development of CVD, pending further investigations to clarify the precise mechanism of action.

**Compliance with ethical standards**

The experimental protocol and procedures were approved by the Institutional Research Ethics Committee of Beni-Suef University (Egypt).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no conflict of interest.

**Acknowledgment**

The authors extend their appreciation to the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University for supporting this research through the Fast-track Research Funding Program.

**References**

Abbas AM, Sakr HF (2013): Simvastatin and vitamin E effects on cardiac and hepatic oxidative stress in rats fed on high fat diet. Journal of physiology and biochemistry 69, 737-750

Al-Rasheed NM, Al-Oteibi MM, Al-Manee RZ, Al-Shareef SA, Hasan IH, Mohamad RA, Mahmoud AM (2015): Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. Drug Des Devel Ther. 2015 Jun 23;9:3217-29. doi: 10.2147/DDDT.S86431. eCollection 2015.

AlSharari SD, Al-Rejaie SS, Abuohashish HM, Ahmed MM, Hafez MM (2016): Rutin attenuates Hepatotoxicity in high-cholesterol-diet-fed rats. Oxidative medicine and cellular longevity 2016, 5436745

Araghi A, Golshahi H, Baghban F, Abouhosseini Tabari M (2018): Ameliorative action of farnesol on cyclophosphamide induced toxicity in mice. Journal of Herbmed Pharmacology 7, 37-43

Arvind A, Osganian SA, Cohen DE, Corey KE (2000): Lipid and Lipoprotein Metabolism in Liver Disease. In: Feingold KR et al. (Editors), Endotext. MDText.com, Inc., South Dartmouth (MA)

Becke AD (1993): Density‐functional thermochemistry. III. The role of exact exchange. The Journal of Chemical Physics 98, 5648-5652

Beutler E, Duron O, Kelly BM (1963): Improved method for the determination of blood glutathione. The Journal of laboratory and clinical medicine 61, 882-888

Bin-Jumah MN (2018): Monolluma quadrangula protects against oxidative stress and modulates LDL receptor and fatty acid synthase gene expression in hypercholesterolemic rats. Oxidative medicine and cellular longevity 2018, 3914384

Bradford MM (1976): A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-54

Cheng F, Wang Q, Chen M, Quiocho FA, Ma JJPS, Function,, Bioinformatics (2008): Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands. 70, 1228-1234

Chirala SS, Wakil SJJL (2004): Structure and function of animal fatty acid synthase. 39, 1045-1053

Cífková R, Krajčoviechová A (2015): Dyslipidemia and cardiovascular disease in women. Current cardiology reports 17, 609

Cohen G, Dembiec D, Marcus J (1970): Measurement of catalase activity in tissue extracts. Anal Biochem 34, 30-38

Corbett JW, Freeman-Cook KD, Elliott R, Vajdos F, Rajamohan F, Kohls D, Marr E, Zhang H, Tong L, Tu MJB, letters mc (2010): Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. 20, 2383-2388

Csonka C, Sárközy M, Pipicz M, Dux L, Csont T (2016): Modulation of hypercholesterolemia-induced oxidative/nitrative stress in the heart. Oxidative medicine and cellular longevity 2016, 3863726

de Souza DS, de Menezes-Filho JER, Santos-Miranda A, de Jesus ICG, Neto JAS, Guatimosim S, Cruz JS, de Vasconcelos CML (2019): Calcium overload-induced arrhythmia is suppressed by farnesol in rat heart. European journal of pharmacology 859, 172488

Emini Veseli B, Perrotta P, De Meyer GRA, Roth L, Van der Donckt C, Martinet W, De Meyer GRY (2017): Animal models of atherosclerosis. Eur J Pharmacol 816, 3-13

Farrell GC, Larter CZ (2006): Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112

Folch J, Lees M, Sloane Stanley GH (1957): A simple method for the isolation and purification of total lipides from animal tissues. The Journal of biological chemistry 226, 497-509

Förstermann U (2008): Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nature Reviews Cardiology 5, 338

Goodridge AG (1972): Regulation of the activity of acetyl coenzyme A carboxylase by palmitoyl coenzyme A and citrate. The Journal of biological chemistry 247, 6946-6952

Goto T, Kim Y-I, Funakoshi K, Teraminami A, Uemura T, Hirai S, Lee J-Y, Makishima M, Nakata R, Inoue H (2011): Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and-independent pathways. American Journal of Physiology-Endocrinology and Metabolism 301, E1022-E1032

Guido S, Joseph T (1992): Effect of chemically different calcium antagonists on lipid profile in rats fed on a high fat diet. Indian journal of experimental biology 30, 292-4

Han Q, Yeung SC, Ip MS, Mak JC (2018): Dysregulation of cardiac lipid parameters in high-fat high-cholesterol diet-induced rat model. Lipids in health and disease 17, 255

Hiyoshi H, Yanagimachi M, Ito M, Yasuda N, Okada T, Ikuta H, Shinmyo D, Tanaka K, Kurusu N, Yoshida I (2003): Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. Journal of lipid research 44, 128-135

Horton JD, Goldstein JL, Brown MS (2002): SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. The Journal of clinical investigation 109, 1125-1131

Huang Y, Walker K, Hanley F, Narula J, Houser S, Tulenko T (2004): Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 109, 97-102

Jahangir T, Khan TH, Prasad L, Sultana S (2005): Alleviation of free radical mediated oxidative and genotoxic effects of cadmium by farnesol in Swiss albino mice. Redox Report 10, 303-310

Jung YY, Hwang ST, Sethi G, Fan L, Arfuso F, Ahn KS (2018): Potential anti-inflammatory and anti-cancer properties of farnesol. Molecules 23, 2827

Kahn BB, Alquier T, Carling D, Hardie DG (2005): AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell metabolism 1, 15-25

Kim EJ, Kim B-h, Seo HS, Lee YJ, Kim HH, Son H-H, Choi MH (2014): Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PloS one 9, e97841

Kim H-L, Jung Y, Park J, Youn D-H, Kang J, Lim S, Lee BS, Jeong M-Y, Choe S-K, Park R (2017): Farnesol has an anti-obesity effect in high-fat diet-induced obese mice and induces the development of beige adipocytes in human adipose tissue derived-mesenchymal stem cells. Frontiers in pharmacology 8, 654

Kocsis GF, Csont T, Varga-Orvos Z, Puskas LG, Murlasits Z, Ferdinandy P (2009): Expression of genes related to oxidative/nitrosative stress in mouse hearts: effect of preconditioning and cholesterol diet. Medical Science Monitor 16, BR32-BR39

Ku C-M, Lin J-Y (2015): Farnesol, a sesquiterpene alcohol in herbal plants, exerts anti-inflammatory and antiallergic effects on ovalbumin-sensitized and-challenged asthmatic mice. Evidence-Based Complementary and Alternative Medicine 2015, 387357

Kubinyi HJPoidr (2001): Hydrogen bonding: the last mystery in drug design. 513-24

Küçükgergin C, Aydın AF, Özdemirler-Erata G, Mehmetçik G, Koçak-Toker N, Uysal M (2010): Effect of artichoke leaf extract on hepatic and cardiac oxidative stress in rats fed on high cholesterol diet. Biological trace element research 135, 264-274

Lara-Guzmán OJ, Gil-Izquierdo Á, Medina S, Osorio E, Álvarez-Quintero R, Zuluaga N, Oger C, Galano J-M, Durand T, Muñoz-Durango K (2018): Oxidized LDL triggers changes in oxidative stress and inflammatory biomarkers in human macrophages. Redox biology 15, 1-11

Lateef A, Rehman MU, Tahir M, Khan R, Khan AQ, Qamar W, Sultana S (2013): Farnesol protects against intratracheally instilled cigarette smoke extract-induced histological alterations and oxidative stress in prostate of wistar rats. Toxicology international 20, 35-42

Lee KS, Chun SY, Kwon YS, Kim S, Nam KS (2017): Deep sea water improves hypercholesterolemia and hepatic lipid accumulation through the regulation of hepatic lipid metabolic gene expression. Molecular medicine reports 15, 2814-2822

Livak KJ, Schmittgen TD (2001): Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-8

Lu S, Archer MC (2005): Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis 26, 153-157

Marklund S, Marklund G (1974): Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European journal of biochemistry 47, 469-74

McGill MR (2016): The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI journal 15, 817-828

Meigs TE, Roseman DS, Simoni RD (1996): Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. Journal of Biological Chemistry 271, 7916-7922

Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ (2012): Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell metabolism 15, 665-674

Muniz LB, Alves-Santos AM, Camargo F, Martins DB, Celes MRN, Naves MMV (2019): High-Lard and High-Cholesterol Diet, but not High-Lard Diet, Leads to Metabolic Disorders in a Modified Dyslipidemia Model. Arquivos brasileiros de cardiologia 113, 896-902

Ohkawa H, Ohishi N, Yagi K (1979): Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical biochemistry 95, 351-358

Ong TP, Heidor R, de Conti A, Dagli ML, Moreno FS (2006): Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 27, 1194-203

Ordovas JM (2009): Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention. The American journal of clinical nutrition 89, 1509S-1517S

Orellana-Gavalda JM, Herrero L, Malandrino MI, Paneda A, Sol Rodriguez-Pena M, Petry H, Asins G, Van Deventer S, Hegardt FG, Serra D (2011): Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. Hepatology 53, 821-832

Osipov RM, Bianchi C, Feng J, Clements RT, Liu Y, Robich MP, Glazer HP, Sodha NR, Sellke FW (2009): Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion. Circulation 120, S22-S30

Pant A, Rondini EA, Kocarek TA (2019): Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells. Toxicology and applied pharmacology 365, 61-70

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004): UCSF Chimera—a visualization system for exploratory research and analysis. Journal of computational chemistry 25, 1605-1612

Qamar W, Sultana S (2008): Farnesol ameliorates massive inflammation, oxidative stress and lung injury induced by intratracheal instillation of cigarette smoke extract in rats: an initial step in lung chemoprevention. Chemico-biological interactions 176, 79-87

Ren R, Gong J, Zhao Y, Zhuang X, Ye Y, Huang F, Lin W (2018): Sulfated polysaccharide from Enteromorpha prolifera suppresses SREBP-1c and ACC expression to lower serum triglycerides in high-fat diet-induced hyperlipidaemic rats. Journal of functional foods 40, 722-728

Ross R (1992): The Pathogenesis of Atherosclerosis. In: Braunwald E (Editor), Heart Disease: A Textbood of Cardiovascular Medicine. PA: WB Saunders, Philadelphia, pp. 1106-1124

Santhanasabapathy R, Vasudevan S, Anupriya K, Pabitha R, Sudhandiran G (2015): Farnesol quells oxidative stress, reactive gliosis and inflammation during acrylamide-induced neurotoxicity: behavioral and biochemical evidence. Neuroscience 308, 212-227

Shi J, Li R, Liu Y, Lu H, Yu L, Zhang F (2019): Shuangyu Tiaozhi Granule Attenuates Hypercholesterolemia through the Reduction of Cholesterol Synthesis in Rat Fed a High Cholesterol Diet. BioMed research international 2019, 4805926

Singh UN, Kumar S, Dhakal S (2017): Study of oxida-tive stress in hypercholesterolemia. Int J Con-temp Med Res 4, 1204-1207

Smathers RL, Galligan JJ, Stewart BJ, Petersen DR (2011): Overview of lipid peroxidation products and hepatic protein modification in alcoholic liver disease. Chemico-biological interactions 192, 107-112

Smith S, Witkowski A, Joshi AKJPilr (2003): Structural and functional organization of the animal fatty acid synthase. 42, 289-317

Sozen E, Ozer NK (2017): Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases: An updated mini-review. Redox biology 12, 456-461

Sun YZ, Chen JF, Shen LM, Zhou J, Wang CF (2017): Anti-atherosclerotic effect of hesperidin in LDLr(-/-) mice and its possible mechanism. Eur J Pharmacol 815, 109-117

Szűcs G, Murlasits Z, Török S, Kocsis GF, Pálóczi J, Görbe A, Csont T, Csonka C, Ferdinandy P (2013): Cardioprotection by farnesol: role of the mevalonate pathway. Cardiovascular drugs and therapy 27, 269-277

Tatman D, Mo H (2002): Volatile isoprenoid constituents of fruits, vegetables and herbs cumulatively suppress the proliferation of murine B16 melanoma and human HL-60 leukemia cells. Cancer letters 175, 129-139

Trott O, Olson AJ (2010): AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry 31, 455-461

van Herpen NA, Schrauwen-Hinderling VB (2008): Lipid accumulation in non-adipose tissue and lipotoxicity. Physiology & behavior 94, 231-241

Varga ZV, Kupai K, Szűcs G, Gáspár R, Pálóczi J, Faragó N, Zvara Á, Puskás LG, Rázga Z, Tiszlavicz L (2013): MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. Journal of molecular and cellular cardiology 62, 111-121

Voziyan PA, Goldner CM, Melnykovych G (1993): Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochemical Journal 295, 757-762

Witkowski A, Joshi AK, Smith SJB (2002): Mechanism of the β-ketoacyl synthase reaction catalyzed by the animal fatty acid synthase. 41, 10877-10887

Xiang S, Callaghan MM, Watson KG, Tong LJPotNAoS (2009): A different mechanism for the inhibition of the carboxyltransferase domain of acetyl-coenzyme A carboxylase by tepraloxydim. 106, 20723-20727


Yang R-L, Shi Y-H, Hao G, Li W, Le G-W (2008): Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index. Journal of clinical biochemistry and nutrition 43, 154-158

Zelcer N, Hong C, Boyadjian R, Tontonoz P (2009): LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science (New York, N.Y.) 325, 100-104


**Table 1.** Primers used for qRT-PCR.

|  |  |  |  |
| --- | --- | --- | --- |
| **Gene** | **Accession number** | **Forward Primer**  **(5'-3')** | **Reverse Primer**  **(5'-3')** |
| *FAS* | NM\_017332 | GCCTAACACCTCTGTGCAGT | GGCAATACCCGTTCCCTGAA |
| *ACC* | NM\_022193 | TTGGTGCTTATATTGTGGATGG | ATGTGCCGAGGATTGATGG |
| *LDLR* | NM\_175762 | CAGCTCTGTGTGAACCTGGA | TTCTTCAGGTTGGGGATCAG |
| *SREBP1c* | NM\_001276707 | CATCAACAACCAAGACAGTG | GAAGCAGGAGAAGAGAAGC |
| *β-actin* | NM\_031144 | AGGAGTACGATGAGTCCGGC | CGCAGCTCAGTAACAGTCCG |


**Figures**




**Figure 1.** Body weight changes in control and HCD-fed rats. FAR and SIM prevented the significant increase in body weight of HCD-fed rats at weeks 8-10. Data are Mean ± SEM, *n* = 6. \*\*\*P<0.001 versus Control and ###P<0.001 FAR (5 and 10 mg) and SIM versus HCD.




**Figure 2.** FAR attenuates dyslipidemia in HCD-fed rats. FAR and SIM reduced serum TG (A), and total- (B), LDL- (C) and vLDL-cholesterol (D) and didn’t increase HDL-cholesterol (E) significantly in HCD-fed rats. Data are Mean ± SEM, *n* = 6. \*\*\*P<0.001 versus Control and ###P<0.001 versus HCD.




**Figure 3.** FAR prevents atherogenesis in HCD-fed rats. FAR and SIM decreased cardiovascular risk indices (A,B) and increased anti-atherogenic index (C). Data are Mean ± SEM, *n* = 6. \*\*\*P<0.001 versus Control and #P<0.05, ##P<0.01 and ###P<0.001 versus HCD.




**Figure 4.** FAR attenuates lipid accumulation in liver of HCD-fed rats. FAR and SIM decreased hepatic cholesterol (A) and triglycerides (B) in HFD-fed rats. Data are Mean ± SEM, *n* = 6. \*\*\*P<0.001 versus Control and #P<0.05 and ##P<0.01 versus HCD.




**Figure 5.** Photomicrographs of liver sections of (A) Control rats showing normal structure of hepatocytes and central vein and no alterations, (B) HCD-fed rats showing vacuolation of round border and clear vacuoles consistent with fatty changes (arrows), (C-E) HCD-fed rats treated with 5 mg/kg FAR (C), 10 mg/kg FAR (D) and SIM (E) showing remarkable improvement of liver architecture with slight vacuolations. (H&E – X400 – Scale bar = 50 µm)**.**




**Figure 6.** FAR prevents liver and heart injury in HCD-fed rats. FAR and SIM reduced serum ALT (A), AST (B), ALP (C) LDH (D) and CK-MB (E) significantly in HCD-fed rats. Data are Mean ± SEM, *n* = 6. \*\*\*P<0.001 versus Control and ##P<0.01 and ###P<0.001 versus HCD.




**Figure 7.** FAR diminishes hepatic LPO and enhances antioxidants in HCD-fed rats. FAR and SIM reduced MDA (A) and increased GSH (B), SOD (C) and CAT (D) in liver of HCD-fed rats. Data are Mean ± SEM, *n* = 6. \*\*P<0.01 and \*\*\*P<0.001 versus Control and #P<0.05, ##P<0.01 and ###P<0.001 versus HCD.



**Figure 8.** FAR suppresses inflammation in HCD-fed rats. FAR and SIM decreased serum CRP (A), TNF-α (B), IL-6 (C) and IL-1β (D) in HCD-fed rats. Data are Mean ± SEM, *n* = 6. \*\*\*P<0.001 versus Control and #P<0.05, ##P<0.01 and ###P<0.001 versus HCD.



**Figure 9.** FAR modulates hepatic LDLR, SREBP-1c, FAS and ACC in HCD-fed rats. FAR and SIM increased hepatic LDLR (A), and decreased SREBP-1c (B), FAS (C) and ACC (E) mRNA abundance and FAS activity in HCD-fed rats. Data are Mean ± SEM, *n* = 6. \*\*\*P<0.001 versus Control and #P<0.05, ##P<0.01 and ###P<0.001 versus HCD.



**Figure 10.** Docking models of FAR with (A) FAS/TE, (B) FAS/KS and (C) ACC.